Long-acting PYY₃ _-36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies.

Total, HDL, and LDL cholesterol levels did not vary much during treatment in either group, whereas a slight trend toward a decreased EOT to baseline ratio could be seen for VLDL cholesterol, triglycerides, and free fatty acids with PYY1875‐1.0 + semaglutide compared with placebo + semaglutide (Figure 4I ).

also in 4,078 other papers